Substituted chiral fused [1,2]imidazo[4,5-C] ring compounds
US8350034B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 2, 2011 |
| Grant date | Jan 8, 2013 |
| Priority date | — |
| Expiry date | Aug 2, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Substituted fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—R1)— group in the fused ring at the 1-position of the imidazo ring, wherein R1 includes a functional group, for example, an amide, sulfonamide, urea, carbamate, ester, ketone, ether, a thio analog of the forgoing, sulfone, oxime, or hydroxylamine, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.